Treatment of post-radioactive iodine relapse of hyperthyroidism: comparison of long-term methimazole and radioactive iodine treatment

Saadat, Navid; Azizi, Fereidoun; Abdi, Hengameh; Amouzegar, Atieh

doi:10.1007/s40618-022-01823-5

Cited by 4 publications

(1 citation statement)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This frequently necessitates long-term CBM use. However, hepatotoxicity and severe neutropenia are uncommon but dangerous side effects of CBM [ 18 ]. It was also noted that LT-MMI treatment produced euthyroidism more quickly and maintained hyperthyroidism better over a 60-month follow-up period; it was superior to radioiodine in patients with post-RAI relapses of hyperthyroidism [ 19 ].…”

Section: Reviewmentioning

confidence: 99%

Unveiling Promising Modalities and Enhancing Patient Outcomes in Graves’ Disease Treatment: A Systematic Review and Meta-Analysis

Almutairi,

Alqadi,

Alsulaim

et al. 2024

Cureus

View full text Add to dashboard Cite

Graves' disease (GD) is an autoimmune condition of the thyroid. The hyperthyroidism manifested by patients affected by this disease is caused by the production of autoantibodies against the thyroid-stimulating hormone (TSH, or thyrotropin) receptor (TSHR), which mimic the effects of the hormone on thyroid cells, thereby stimulating autonomic production of thyroxine and triiodothyronine. Deciding on a therapeutic approach to this condition presents intricate dilemmas for both clinicians and patients. Each of the three available treatment modalities is grounded in evidence-based medicine, affirming its efficacy. This systematic review and meta-analysis aimed to assess the effect of carbimazole (CBM), radioactive iodine (RAI), and surgery in treating GD and provide evidence-based recommendations for healthcare providers regarding the optimal management of the condition based on a comprehensive analysis of effectiveness, safety, patient satisfaction, and recovery outcomes. This systematic review and meta-analysis adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We used the PubMed and Google Scholar databases to conduct a thorough web search for articles published between January 2019 and September 2023. The meta-analysis was carried out using Resource Manager (Revman) 5.4.1. The study found that propylthiouracil (PTU) or methimazole/carbimazole (MMI/CBM) treatment increases the risk of hyperlipidemia in patients with hyperthyroidism. Once in a euthyroid state, glucose tolerance increases; for children with GD, a computer model for customized dosing has been created. To sum up, CBM, surgery, and RAI are all useful treatment options for GD. Using steroids in conjunction with radiation therapy may help prevent Graves' ophthalmopathy (GO).

show abstract

Section: Reviewmentioning

confidence: 99%

Unveiling Promising Modalities and Enhancing Patient Outcomes in Graves’ Disease Treatment: A Systematic Review and Meta-Analysis

Almutairi,

Alqadi,

Alsulaim

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

A short review of current knowledge regarding long-term treatment of Graves’ disease with antithyroid drugs

Giordani,

Sykiotis

2024

Hormones

View full text Add to dashboard Cite

Graves’ disease is the most common form of hyperthyroidism, especially in younger people. Current European guidelines recommend antithyroid drugs as initial treatment for a period limited to 12–18 months. Definitive treatment such as surgery or radioactive iodine is proposed in the case of contraindication to antithyroid drugs or in the case of recurrence after medical treatment. However, more recent studies show that long-term antithyroid treatment is associated with reduced risk of recurrence without an increase in adverse effects. Such data support the option of long-term treatment of Graves’ disease with antithyroid drugs and suggest the necessity for a change to long-standing practices in the field. Herein, after reviewing some general knowledge on Graves’ disease treatment, we discuss the evidence regarding long-term treatment of Graves’ disease with antithyroid drugs for endocrinologists, internists, and other specialists involved in the management of these patients. We consider the main studies in the field, outline their respective strengths and limitations, and, finally, present our opinion on when, in the light of this new evidence, endocrinologists should consider long-term treatment with antithyroid drugs.

show abstract

Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine

Azizi¹,

Abdi²,

Mehran³

et al. 2023

Endocrine Practice

View full text Add to dashboard Cite

Treatment of post-radioactive iodine relapse of hyperthyroidism: comparison of long-term methimazole and radioactive iodine treatment

Cited by 4 publications

References 27 publications

Unveiling Promising Modalities and Enhancing Patient Outcomes in Graves’ Disease Treatment: A Systematic Review and Meta-Analysis

Unveiling Promising Modalities and Enhancing Patient Outcomes in Graves’ Disease Treatment: A Systematic Review and Meta-Analysis

A short review of current knowledge regarding long-term treatment of Graves’ disease with antithyroid drugs

Long-Term Follow-up of Graves Orbitopathy After Treatment With Short- or Long-Term Methimazole or Radioactive Iodine

Contact Info

Product

Resources

About